Entera Bio (ENTX) Return on Sales (2019 - 2025)
Entera Bio (ENTX) posted quarterly Return on Sales of 2.84% for Q4 2025, down 255.0% year-on-year from 1.83% in Q4 2024, and down 215.91% on a QoQ basis from 0.9% in Q3 2025.
Entera Bio (ENTX) Return on Sales (2019 - 2025) Analysis & Trends
Entera Bio (ENTX) has reported Return on Sales for 7 consecutive years, with 2.84% the latest figure, recorded in Q4 2025.
- Quarterly Return on Sales fell 255.0% year-over-year to 2.84% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2.84% (down 229.0% YoY) and the FY2025 annual result came in at 2.72%, down 220.0% from the prior year.
- Return on Sales eased to 2.84% in Q4 2025 per ENTX's latest filing, from 0.9% in the prior quarter.
- Over the last five years, Return on Sales for ENTX reached as high as 0.15% in Q1 2021 and fell as low as 7.09% in Q3 2023.
- A 5-year average of 1.57% and a median of 0.68% in 2024 frame the typical range for Return on Sales.
- Annual changes were most pronounced in 2023 — Return on Sales tumbled 410 bps — and 2024, when it surged 637 bps.
- Year by year, Return on Sales stood at 0.25% in 2021, then tumbled by 772 bps to 2.17% in 2022, then tumbled by 227 bps to 7.09% in 2023, then surged by 96 bps to 0.29% in 2024, then plunged by 887 bps to 2.84% in 2025.
- According to Business Quant data, Return on Sales over the past three periods registered 2.84%, 0.9%, and 0.65% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.84% |
| Sep 30, 2025 | -0.90% |
| Jun 30, 2025 | -0.65% |
| Mar 31, 2025 | -0.62% |
| Dec 31, 2024 | -0.29% |
| Sep 30, 2024 | -0.72% |
| Jun 30, 2024 | -0.43% |
| Sep 30, 2023 | -7.09% |
| Jun 30, 2023 | -4.83% |
| Mar 31, 2023 | -1.74% |
| Dec 31, 2022 | -2.17% |
| Sep 30, 2022 | -3.83% |
| Jun 30, 2022 | -0.72% |
| Mar 31, 2022 | -0.56% |
| Dec 31, 2021 | -0.25% |
| Sep 30, 2021 | -0.23% |
| Jun 30, 2021 | -0.24% |
| Mar 31, 2021 | -0.15% |
| Jun 30, 2020 | -0.61% |
| Jun 30, 2019 | -0.27% |